Paladin Labs Completes Arrangement

NEWS RELEASE TRANSMITTED BY Marketwired 
FOR: Paladin Labs Inc. 
TSX SYMBOL:  PLB 
FEBRUARY 28, 2014 
Paladin Labs Completes Arrangement 
MONTREAL, QUEBEC--(Marketwired - Feb. 28, 2014) -  
THIS MEDIA RELEASE IS NOT FOR DISTRIBUTION TO THE UNITED STATES NEWSWIRE
SERVICES OR FOR DISSEMINATION IN THE UNITED STATES 
Paladin Labs Inc. (TSX:PLB) ("Paladin" or the
"Corporation"), a leading Canadian specialty pharmaceutical company,
is pleased to announce the completion of the indirect acquisition by Endo
International plc ("New Endo") of all of the outstanding shares of
the Corporation (the "Arrangement"). Under the terms of the
Arrangement, Endo Health Solutions Inc. ("Endo") and Paladin have
been combined under New Endo.  
Paladin shareholders will receive (i) 1.6331 shares of New Endo, (ii) CDN$1.16
cash and (iii) one share of Knight Therapeutics Inc. ("Knight"), a
newly formed Canadian company, for each Paladin share they owned upon closing.  
Shares of Knight will trade on the TSX Venture Exchange under the ticker symbol
GUD. Shares of New Endo will trade on NASDAQ under the ticker symbol ENDP and
the Toronto Stock Exchange under the ticker symbol ENL. Trading in New Endo and
Knight shares is expected to commence on Monday, March 3, 2014. 
"I am thrilled to have led the outstanding Paladin team for almost the
last two decades to such a rewarding outcome," said Jonathan Ross Goodman,
Chairman of Paladin. "I look forward to leading Knight and building a team
of excellence that will be as rewarding for all."  
Mark Beaudet, Interim CEO of Paladin added, "I would like to thank the
management team, employees and directors of Paladin for their dedication to
growing our business. The value attributed to the Company in the transaction
with Endo is a testament to the incredible things that we have achieved
together. With this transaction we are well positioned to continue our growth
plan and I'm looking forward to continuing Paladin's great track
record of success within the New Endo team." 
About Paladin Labs Inc.  
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty
pharmaceutical company focused on acquiring or in-licensing innovative
pharmaceutical products for the Canadian and world markets. With this strategy,
a focused national sales team and proven marketing expertise, Paladin has
evolved into one of Canada's leading specialty pharmaceutical companies.
For more information about Paladin, please visit the Corporation's web
site at www.paladinlabs.com.  
About Endo 
Endo International plc is a global specialty healthcare company focused on
improving patients' lives while creating shareholder value. Endo develops,
manufactures, markets, and distributes quality branded pharmaceutical, generic
and device products through its operating companies. Endo has global
headquarters in Dublin, Ireland and US headquarters in Malvern PA. Learn more
at www.endo.com.  
About Knight Therapeutics Inc. 
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty
pharmaceutical company focused on acquiring or in-licensing innovative
pharmaceutical products for the Canadian and world markets. The TSX Venture
Exchange has conditionally approved the listing of Knight Therapeutics'
shares subject only to customary conditions. For more information about Knight
Therapeutics, please visit www.sedar.com. 
This press release may contain forward-looking statements and predictions.
These forward-looking statements, by their nature, necessarily involve risks
and uncertainties that could cause actual results to differ materially from
those contemplated by the forward-looking statements. The Corporation considers
the assumptions on which these forward-looking statements are based to be
reasonable at the time they were prepared, but cautions that these assumptions
regarding the future events, many of which are beyond the control of the
Corporation and its subsidiaries, may ultimately prove to be incorrect. Factors
and risks that could cause actual results to differ materially from current
expectations are discussed in the annual report as well as in the
Corporation's Annual Information Form for the year ended December 31,
2012. The Corporation disclaims any intention or obligation to update or revise
any forward-looking statements whether as a result of new information or future
events and except as required by law. For additional information on risks and
uncertainties relating to these forward-looking statements, investors should
consult the Corporation's ongoing quarterly filings, annual report and
Annual Information Form and other filings found on SEDAR at www.sedar.com.  
-30-
FOR FURTHER INFORMATION PLEASE CONTACT: 
CST Phoenix Advisors
Toll Free: 1-800-239-6813
inquiries@phoenixadvisorscst.com 
INDUSTRY:  Pharmaceuticals and Biotech - Biotech, Pharmaceuticals and Biotech -
Drugs, Pharmaceuticals and Biotech - Equipment and Supplies, Pharmaceuticals
and Biotech - Trials 
SUBJECT:  STK 
-0-
-0- Feb/28/2014 13:30 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.